OBJECTIVE: To determine the prevalence of autoantibodies directed against an epitope of the glutamate/N-methyl-D-aspartic acid (NMDA) receptor subunit NR2A (which is highly expressed in human brain) in the sera of lupus patients, and to investigate the possible correlation of these antibodies with clinical and serological manifestations of systemic lupus erythematosus (SLE). METHODS: Sera were obtained from 109 consecutive SLE patients. Controls were 65 patients with myasthenia gravis, 19 with autoimmune polyendocrine syndrome type I (APS I), and 65 healthy donors. A 15 amino acid long peptide based on a sequence within the NR2A subunit of the NMDA/glutamate receptor was synthesised. Antibodies to this peptide were determined by enzyme linked immunosorbent assay. Antibodies against double stranded DNA (dsDNA) were measured by Chrithidia luciliae assay. Disease activity was determined using the SLE disease activity index (SLEDAI). RESULTS: Sera of 34/109 SLE patients (31%) reacted specifically with the NR2A peptide compared with only 4/65 myasthenia gravis patients (6.1%, p<0.001), 1/19 APS I patients (5.3%, p<0.02), and 3/65 healthy controls (4.6%, p<0.001). No correlation was found between the presence of NR2A and dsDNA or anti-cardiolipin specific autoantibodies. In addition, no significant correlation was observed between the presence of NR2A specific antibodies and the SLEDAI score or any lupus related clinical manifestations. CONCLUSIONS: A significant number of SLE patients (31%) have NR2A specific antibodies that do not correlate with anti-dsDNA antibodies. Additional studies of lupus patients with neurological disorders should elucidate the role of NR2A specific antibodies in lupus related CNS manifestations.
OBJECTIVE: To determine the prevalence of autoantibodies directed against an epitope of the glutamate/N-methyl-D-aspartic acid (NMDA) receptor subunit NR2A (which is highly expressed in human brain) in the sera of lupuspatients, and to investigate the possible correlation of these antibodies with clinical and serological manifestations of systemic lupus erythematosus (SLE). METHODS: Sera were obtained from 109 consecutive SLEpatients. Controls were 65 patients with myasthenia gravis, 19 with autoimmune polyendocrine syndrome type I (APS I), and 65 healthy donors. A 15 amino acid long peptide based on a sequence within the NR2A subunit of the NMDA/glutamate receptor was synthesised. Antibodies to this peptide were determined by enzyme linked immunosorbent assay. Antibodies against double stranded DNA (dsDNA) were measured by Chrithidia luciliae assay. Disease activity was determined using the SLE disease activity index (SLEDAI). RESULTS: Sera of 34/109 SLEpatients (31%) reacted specifically with the NR2A peptide compared with only 4/65 myasthenia gravispatients (6.1%, p<0.001), 1/19 APS Ipatients (5.3%, p<0.02), and 3/65 healthy controls (4.6%, p<0.001). No correlation was found between the presence of NR2A and dsDNA or anti-cardiolipin specific autoantibodies. In addition, no significant correlation was observed between the presence of NR2A specific antibodies and the SLEDAI score or any lupus related clinical manifestations. CONCLUSIONS: A significant number of SLEpatients (31%) have NR2A specific antibodies that do not correlate with anti-dsDNA antibodies. Additional studies of lupuspatients with neurological disorders should elucidate the role of NR2A specific antibodies in lupus related CNS manifestations.
Authors: Jukka Loukkola; Matti Laine; Hanna Ainiala; Jukka Peltola; Riina Metsänoja; Anssi Auvinen; Aki Hietaharju Journal: J Clin Exp Neuropsychol Date: 2003-02 Impact factor: 2.475
Authors: Giovanni Sanna; Maria L Bertolaccini; Maria J Cuadrado; Hana Laing; Munther A Khamashta; Alessandro Mathieu; Graham R V Hughes Journal: J Rheumatol Date: 2003-05 Impact factor: 4.666
Authors: Y Takahashi; H Mori; M Mishina; M Watanabe; T Fujiwara; J Shimomura; H Aiba; T Miyajima; Y Saito; A Nezu; H Nishida; K Imai; N Sakaguchi; N Kondo Journal: Neurology Date: 2003-10-14 Impact factor: 9.910
Authors: Svetlana A Dambinova; Guerman A Khounteev; Galina A Izykenova; Igor G Zavolokov; Anna Y Ilyukhina; Alexander A Skoromets Journal: Clin Chem Date: 2003-10 Impact factor: 8.327
Authors: Thomas W Faust; Eric H Chang; Czeslawa Kowal; RoseAnn Berlin; Irina G Gazaryan; Eva Bertini; Jie Zhang; Jorge Sanchez-Guerrero; Hilda E Fragoso-Loyo; Bruce T Volpe; Betty Diamond; Patricio T Huerta Journal: Proc Natl Acad Sci U S A Date: 2010-10-04 Impact factor: 11.205
Authors: Brian E Jones; Kenneth R Tovar; April Goehring; Farzad Jalali-Yazdi; Nana J Okada; Eric Gouaux; Gary L Westbrook Journal: Sci Transl Med Date: 2019-07-10 Impact factor: 17.956
Authors: Jessy John Alexander; Aileen Judith Anderson; Scott Robert Barnum; Beth Stevens; Andrea Joan Tenner Journal: J Neurochem Date: 2008-10-24 Impact factor: 5.372